PDS BIOTECHNOLOGY CORPORATION - COMMON STOCK

1,2350

08-мая-25 14:39:55

15 мин. задержка

Акции

+0,0750

+6,47%

Сегодняшний диапазон

1,1600 - 1,2700

ISIN

N/A

Источник

NASDAQ

PDS Biotech Announces Presentation of Rationale and Design of First Recurrent Prostate Cancer Trial to Combine an Androgen Receptor Pathway Inhibitor with an Immunocytokine

22 окт 2024 08:00:01 Источник Nasdaq GlobeNewswire
PDS Biotech Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune® HPV and Chemoradiation

02 окт 2024 08:00:00 Источник Nasdaq GlobeNewswire
PDS Biotech Announces Updated Results from VERSATILE-002 Phase 2 Clinical Trial Presented at ESMO 2024

16 сен 2024 07:00:00 Источник Nasdaq GlobeNewswire
PDS Biotech to Present Updated VERSATILE-002 Data at ESMO Congress 2024

09 сен 2024 08:00:47 Источник Nasdaq GlobeNewswire
PDS Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference

03 сен 2024 08:00:00 Источник Nasdaq GlobeNewswire
PDS Biotech Provides Business Update and Reports Second Quarter 2024 Financial Results

13 авг 2024 08:00:00 Источник Nasdaq GlobeNewswire
PDS Biotech Announces Abstract Accepted for Oral Presentation at 2024 ASTRO Annual Meeting

08 авг 2024 08:00:01 Источник Nasdaq GlobeNewswire
PDS Biotech to Announce Second Quarter Financial Results on August 13, 2024

07 авг 2024 08:00:00 Источник Nasdaq GlobeNewswire
PDS Biotech Announces Abstract Accepted for Presentation at ESMO Congress 2024

05 авг 2024 08:00:00 Источник Nasdaq GlobeNewswire
PDS Biotech Aligns with FDA on Phase 3 Trial in HPV16-Positive First-Line Recurrent or Metastatic Head and Neck Cancer

01 авг 2024 07:45:00 Источник Nasdaq GlobeNewswire
PDS Biotech to Host Clinical Program Update Conference Call on August 1, 2024, at 8 a.m. Eastern Time

31 июл 2024 16:01:00 Источник Nasdaq GlobeNewswire
PDS Biotech to Participate at BTIG Virtual Biotechnology Conference

29 июл 2024 08:00:00 Источник Nasdaq GlobeNewswire
PDS Biotech Provides Data Update from Ongoing VERSATILE-002 Phase 2 Clinical Trial in Head and Neck Cancer

12 июн 2024 08:00:00 Источник Nasdaq GlobeNewswire
PDS Biotech Provides Business Update and Reports First Quarter 2024 Financial Results

15 май 2024 08:00:00 Источник Nasdaq GlobeNewswire
PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer

09 май 2024 17:46:46 Источник Nasdaq GlobeNewswire
PDS Biotech to Participate in Upcoming May 2024 Investor Conferences

09 май 2024 08:00:00 Источник Nasdaq GlobeNewswire
PDS Biotech to Announce First Quarter 2024 Financial Results on May 15, 2024

07 май 2024 08:00:01 Источник Nasdaq GlobeNewswire
PDS Biotechnology Announces Details of Virtual KOL Event

03 май 2024 08:00:00 Источник Nasdaq GlobeNewswire
PDS Biotech Appoints Stephan Toutain as Chief Operating Officer

02 май 2024 08:00:00 Источник Nasdaq GlobeNewswire
PDS Biotech to Host Key Opinion Leader Event to Discuss Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer

23 апр 2024 08:00:00 Источник Nasdaq GlobeNewswire

<<
<
1
2
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.